Immunomodulators, proteasome inhibitors and monoclonal antibodies for multiple myeloma

There is currently no standard treatment for patients with relapsed or refractory multiple myeloma. At the 20th Congress of the European Hematology Association (EHA), Pieter Sonneveld, MD, of the Erasmus MC University Cancer Institute, Rotterdam, the Netherlands, discusses promising agents for this patient population, including immunomodulatory agents, such as lenalidomide and pomalidomide; proteasome inhibitors, such as carfilzomib; and monoclonal antibodies, such as daratumumab and elotuzumab.

Share this video